The IBRI fills a major research gap by connecting academic discovery and industry development, and public and private enterprise to improve human health.

What

  • The Indiana Biosciences Research Institute (IBRI) is a 501(c)(3) not-for-profit and independent applied research institute formed in 2013. Our motto is Discovery With Purpose, reflecting our commitment to the translation of scientific discovery into improved outcomes. 
  • Founders of the IBRI were Lilly Endowment, the state of Indiana, Eli Lilly and Company Foundation, Roche Diagnostics, Dow AgroSciences (now Corteva Agriscience), Eli Lilly and Company, Indiana University Health, Cook Medical, Indiana University School of Medicine and the city of Indianapolis.

Why

  • Indiana’s life sciences economy comprises 1,689 companies employing 55,000 with $90,000+ annual salaries and has a $78 billion-dollar annual economic impact to the state.
  • In 2012, Indiana state, civic, corporate and academic leaders called for creating an independent applied research institute to serve as a novel, mutually beneficial bridge between industry and academia. The goal is to capture and accelerate game-changing, outcome-driven research—both industry-sponsored and publicly funded—through the attraction and retention of world-class talent to the IBRI.
  • The IBRI exists to bring together companies and universities to work collaboratively on interrelated health issues that are of both global significance and have a disproportionate impact on Hoosiers—diabetes, metabolic disease and poor nutrition.

Where

  • The IBRI’s labs and offices are currently housed in 18,000-square feet of leased space in the Indiana University School of Medicine’s Biotechnology Research and Training Center (BRTC) at 1345 W. 16th Street on Indianapolis’ near-westside on the border of the planned 16 Tech Innovation District.
  • With groundbreaking scheduled for late 2018, the IBRI will anchor 68,000 square feet of the new Building One in 16 Tech with office, innovation, collaboration and lab space. Completion is scheduled for mid-2020. 

Who

  • The IBRI employs 35 full-time scientific and administrative employees, and up to a dozen students and interns for its research teams.
  • The IBRI's leadership includes:
    • Rainer Fischer, Ph.D., Chief Executive Officer, Chief Scientific and Innovation Officer
    • Mark Andersen, CPA, CFA, Chief Financial Officer, Vice President of Administration
    • Robert Considine, Ph.D., Professor of Medicine, Director, the Diabetes Center
    • Stephanie Grinage, Vice President for Advancement
    • Steven Haney, Ph.D., Research Fellow, the Pharmaceutical Biotechnology Center
    • Teresa Mastracci, Ph.D., Senior Scientist, Director, the Regenerative Medicine and Metabolic Biology Group
    • Jay McGill, Ph.D., Chief Operating Officer
    • Michael Pugia, Ph.D., Research Fellow, Director, the Single Cell Analytics Center
    • Daniel Robertson, Ph.D., Research Fellow, Director, the Applied Data Sciences Center, Vice President of Digital Technology
    • Victor Wroblewski, Ph.D., Research Fellow, the Pharmaceutical Biotechnology Center
    • Vidadi Yusibov, Ph.D., Senior Research Fellow, Director, the Pharmaceutical Biotechnology Center

When

  • By attracting new and retaining existing talent, the IBRI’s goal over the next five years is to build a world-class organization of researchers, innovators and entrepreneurs who will catalyze scientific discovery and its application, resulting in improved health and nutrition outcomes for patients.

How

  • The IBRI was initially funded with $50 million provided by the state of Indiana, Lilly Endowment, Eli Lilly and Company, Roche Diagnostics, Dow AgroSciences, IU Health and Indiana University. In 2016, the institute received an additional $88.5 million in funding commitments from Lilly Endowment, Eli Lilly and Company Foundation and Cook Medical. In 2017 the institute received an additional $20 million commitment from the state of Indiana.
  • The IBRI is looking to expand its partnerships with life sciences and IT companies and philanthropic organizations, and individual donors, worldwide to increase the potential for research, discovery, translation and collaboration. For more information about donation opportunities, please visit http://www.indianabiosciences.org/giving/ 

 

The IBRI’s Mission, Vision, Values

  • MISSION: To become the leading independent, industry-inspired applied research institute in the discovery and development of innovative solutions to improve health, targeting diabetes, metabolic disease and poor nutrition.
  • VISION: Build a world-class organization that catalyzes activities across Indiana’s life sciences community and beyond.
  • VALUES: Scientific excellence, an entrepreneurial mindset and a collaborative nature.

The IBRI’s Research Areas

  • The IBRI is focused on discovery and applied research to facilitate the development of technologies and innovations aimed at improving human and animal health, agriculture and the environment.
  • The Diabetes Center 
    Dr. Considine and his team are studying the molecular basis of diabetes and its complications. In one focus area, Dr. Mastracci’s lab is using zebrafish, mice and human tissue to explore mechanisms for beta cell regeneration. This center is actively recruiting diabetes investigators to the Lilly Diabetes Center of Excellence at the IBRI.
  • The Single Cell Analytics Center 
    Dr. Pugia and his team are working with industry and academic partners to commercialize a platform to make diagnosis of infections and diseases possible from ultimately, a single cell.
  • The Applied Data Sciences Center 
    Dr. Robertson and his team are making vast amounts of health data accessible for analysis by industry and academic partners to better identify and predict human diseases.
  • The Pharmaceutical Biotechnology Center 
    Dr. Yusibov and the team he is assembling will focus on human health concerns through the development and manufacturing of therapeutic antibodies and vaccines. The center will have interdisciplinary science teams working together on a common goal.

Governance

  • The Board of Directors supervises the IBRI management structure. There are currently 11 members, including a representative of the state of Indiana, the CEO of the IBRI, and other high-level members representing the life sciences industry, research institutions, investors, donor organizations and regional universities.
  • The IBRI's Scientific Advisory Board provides guidance on the direction and implementation of research and development. There are currently 11 members, including the IBRI’s Chief Executive Officer/Chief Innovative and Scientific Officer (CEO/CSIO).
  • The Executive Leadership Team is responsible for the day-to-day operations of the IBRI and is comprised of the CEO/CSIO, COO and CFO.

Media Contact
Mark Craft
Executive Director of Engagement, Communications and External Affairs
Office: 317-983-3313
Mobile: 317-670-2270
mcraft@indianabiosciences.org